Immune response following COVID-19 vaccination in children with cancer

Immune responses in childrens with cancer during and shortly after end of treatment seems to be perturbed due to interference with B cell development and lack of T-cell help. This may have important consequences both on the quantity but also quality(glycosylation) of the antibody response, and thereby affect the clinical response. Therefore, in our current study proposal, we want to follow-up the effect of SARS-COV-2 vaccination in the vaccinated patients, as it is not yet clear to what extent they are able to generate both a humoral and/or cellular response against SARS-COV-2 with the regular vaccination scheme. If not, these children may need additional vaccinations to become protected.



In addition, by studying the association between the immune response with details on the disease status, treatment phase and immune-status at vaccination, this study will generate data on which rational future vaccination strategies in this patient category at great risk of infections, can be based on.

PRIMARY OBJECTIVE:

-To assess the antibody response after mRNA (Pfizer, Moderna) SARS-CoV-2 vaccination in children with cancer



SECONDARY OBJECTIVES:

To assess in children with cancer after SARS-CoV 2 vaccination:

- durability of the antibody response

- SARS-CoV-2-specific T and B cell response

- antibody response as compared to healthy children

- the contribution of a 3rd vaccination



EXPLORATORY OBJECTIVES:

To assess in children with cancer after SARS-CoV 2 vaccination:

- the association between baseline disease and immune parameters and the immune response to SARS-CoV-2 vaccination

- the neutralizing capacity of anti-COVID-19 antibodies

- the reported incidence of SARS-CoV-2 infection and outcome of COVID-19 disease 12 months after SARS-CoV-2 vaccination

This is a prospective cohort study to evaluate the efficacy of SARS-CoV-2 vaccination in children with cancer. The study includes 4patient cohorts, which will be analysed together to answer the research questions.

Comirnaty

There is no study-related risk. The burden is minimal. Participation in this study requires a maximum of 5 visits (cohort I) or 3 visits(cohort II, cohort III, and cohort IV) for blood draws at the hospital. Potentially eligible subjects who decide not to participate in the study will still have access to the general national SARS-CoV-2 vaccination program.